Australia · Delayed Price · Currency is AUD Mayne Pharma Group Earnings Call Transcripts
Fiscal Year 2026
-
After a failed takeover and significant share price drop, the company has shifted to branded pharma, launched DistributeRx™ to streamline U.S. distribution, and is focused on growing Women's Health and Dermatology. Key growth drivers include new distribution models and increased menopause therapy adoption.
-
DistributeRx's launch marks a strategic shift to direct-to-patient pharmaceutical distribution, reducing intermediaries and improving profitability. The model leverages existing infrastructure, delivers transparent pricing, and is highly scalable, with strong early adoption in dermatology and significant growth potential as the U.S. cash pay market expands.
-
Revenue was flat at AUD 212.1m, but gross margin rose to 65.3% and underlying EBITDA was AUD 28.6m, down 8%. Dermatology drove margin gains, while women's health saw strong demand but higher investment. Leadership transition and legal actions mark significant developments.
-
The AGM highlighted strong FY 2025 financial results, strategic focus on branded products, and Board changes. Shareholders raised concerns on royalties, dividends, and the failed Cosette takeover. All resolutions were put to poll, with no proxy advisor opposition.
Fiscal Year 2025
-
FY25 saw 5% revenue growth to $408.1 million, with gross margin up to 60.6% and EBITDA more than doubling. Women's health led growth, while dermatology faced generic competition but improved margins. The Cosette acquisition scheme received strong shareholder support.
-
Shareholders considered and voted on a proposed full acquisition by Cosette, with the board and an independent expert recommending approval. The scheme's implementation depends on court and regulatory approvals, and ongoing litigation with Cosette presents key risks.
-
Revenue rose 43% to $188M in H1 FY2024, with all business units delivering positive direct contribution and underlying EBITDA swinging to $8M. Cost optimization, new product launches, and operational improvements drove margin expansion, with positive cash flow and EBITDA expected for the full year.
Fiscal Year 2024
-
The AGM highlighted strong financial and operational improvements, with revenue up 112% and a return to positive EBITDA. Strategic focus remains on growth in women's health, dermatology, and international markets, while addressing legal and market challenges.
-
FY 2024 saw a dramatic turnaround with 112% revenue growth, positive EBITDA, and all segments contributing positively. Key drivers included strong Women's Health and Dermatology performance, successful new product launches, and effective cost control.